Von Recklinghausen's disease, or neurofibromatosis type I, is a common inherited tumor predisposition syndrome with an overall incidence of approximately 1 in 3,000 worldwide. Affected individuals are prone to the development of benign tumors, such as neurofibromas, and malignant cancers, including glioma, malignant peripheral nerve sheath tumors, and leukemia (28, 59 ). The disease is characterized by inactivating mutations of the Neurofibromatosis-1 (NF1) gene (11, 17, 61) , which indicates that NF1 is a tumor suppressor gene. Patients with mutant NF1 are at increased risk for clonal myeloproliferative diseases, including juvenile monomyelocytic leukemia (JMML) (59, 60) . In contrast, NF1 mutation has rarely been detected in acute myeloid leukemia (AML) (29, 42, 55, 56) .
Relatively small reductions in the expression of NF1 produce phenotypic changes in cell proliferation. For example, Nf1 ϩ/Ϫ astrocytes exhibit increased cell proliferation and motility (3) . Similarly, loss of only one NF1 allele is sufficient to partially complement defects in coat color and mast cells in mice containing mutations in the c-Kit receptor tyrosine kinase (W 41 mice) that attenuate Ras-dependent signaling (26) . In addition, repression of NF1 by human immunodeficiency virus Tax predisposes transgenic mice expressing Tax to neurofibromas, indicating that loss of NF1 expression by transcriptional regulation, rather than NF1 mutational inactivation, is sufficient to promote tumorigenesis (16) . These effects are due in part to the role of the NF1 gene product, neurofibromin, as a negative regulator of RAS and other small GTP binding proteins, acting to accelerate GTP hydrolysis (5, 11, 25) . Loss of NF1 results in increased RAS-mediated signaling in response to multiple stimuli, including granulocyte-macrophage colonystimulating factor (GM-CSF), leading to excessive proliferation and increased cell survival of lymphoid and myeloid progenitor cells (26, 35, 67) .
RUNX1 (runt-related 1, also known as AML 1 or AML1) is a DNA binding transcription factor that acts as a molecular switch to activate or repress transcription. Although RUNX1 can associate with coactivators, it appears to activate transcription through composite sites in which the RUNX1 DNA binding site is adjacent to sites for factors that RUNX1 can physically associate with, such as C/EBP␣, PU.1, and ETS1, to form an active transcriptional complex (22, 31, 54, 57, 64, 66) . For example, when expressed alone, RUNX1, C/EBP␣, and PU.1 are poor activators of the M-CSF promoter. However, when coexpressed, RUNX1 synergizes with C/EBP␣ or PU.1 to potently activate transcription (54) . Conversely, when expressed in some cell types, RUNX1 is capable of repressing transcription through the recruitment of mSin3 and Groucho corepressors and histone deacetylases (HDACs) (13, 38, 46) .
The function of RUNX1 is perhaps disrupted more than any other transcription factor in acute leukemia. Chromosomal translocations that affect RUNX1 include t (12;21) , which is present in 20 to 25% of pediatric acute B-cell lymphoblastic leukemias, and t (8;21) , which is the most frequent chromosomal translocation associated with AML, accounting for 10 to 15% of the cases (58) . In addition, inv (16) , which may be the second most frequent chromosomal abnormality in AML (58) , fuses the RUNX1-interacting factor, core binding factor ␤ (CBF␤), to a smooth-muscle myosin heavy-chain gene (40) . The inv (16) fusion protein dominantly inactivates RUNX1-dependent transactivation and stimulates RUNX1-dependent repression (1, 13, 30, 44) . t(8;21) creates a fusion protein that acts as a transcriptional repressor by fusing the N-terminal DNA binding domain of RUNX1 to a putative transcriptional corepressor known as MTG8 (myeloid translocation gene on chromosome 8, also known as eight-twenty-one or ETO). MTG8 contacts both the mSin3 and N-CoR families of corepressors, as well as HDAC1, HDAC2, and HDAC3 (2, 21) . Thus, repression of RUNX1-regulated genes may contribute to leukemogenesis in over 20% of acute leukemias.
Given that the levels of expression of NF1 in AML may be epigenetically altered or transcriptionally regulated, rather than the locus mutated (41, 42) , we asked whether the master regulatory factors C/EBP␣ and RUNX1, which are mutated in AML, might regulate NF1. We found multiple RUNX1, ETS, and C/EBP␣ DNA binding sites, some of which were clustered as in other genes regulated by these factors. RUNX1 and C/EBP␣ independently activated the NF1 promoter and cooperated to dramatically activate NF1. By contrast, the t(8;21) fusion protein, which disrupts RUNX1 and represses C/EBP␣ (52) , repressed the NF1 promoter in reporter assays and repressed expression of the endogenous NF1 gene. Like inactivation of NF1 in individuals with neurofibromatosis, RUNX1-MTG8 expression sensitized myeloid progenitor cells to proliferation in response to GM-CSF, but not interleukin-3 (IL-3). These data suggest that repression of NF1 may contribute to t(8;21)-mediated leukemogenesis.
MATERIALS AND METHODS
Cell culture, reporter assays, and plasmids. HEL, Kasumi-1, HeLa, COS7-L (Invitrogen), and GP2-293 cells were cultured as previously described (2, 39) . The NF1 promoter fragment was subcloned into pGL2-basic (Promega) and the promoter deletions created by restriction digest and religation at the indicated positions relative to the transcriptional start site (18) . Expression plasmids for RUNX1, C/EBP␣, ETS2, PU.1, and RUNX1-MTG8 and its mutants were described previously (6, 34, 39, 65) . Transfection was performed in 6-well or 12-well plates with 1 g of NF1-luciferase plasmid unless otherwise indicated using Polyfect (QIAGEN). Firefly luciferase activity was measured using the Luciferase Assay kit (Promega) and corrected for transfection efficiency by including plasmids expressing Renilla luciferase or secreted alkaline phosphatase (45) .
ChIP. Chromatin immunoprecipitation (ChIP) was performed according to the Upstate Biotechnologies ChIP assay protocol with Kasumi-1 or HeLa cells and 4.0 g of each antibody (see Fig. 3 and Fig. 6 ). After immunoprecipitation overnight at 4°C, DNA was purified by QIAquick PCR Purification kit (QIA-GEN) and 5% of the purified products were used for PCR templates. Promoter sequences were detected with the following PCR primers for NF1: a (forward, Ϫ2313 to Ϫ2291; reverse, Ϫ2133 to Ϫ2159), 5Ј-GGCCTGAAGTTTGGGTGT CTTA-3Ј and 5Ј-TGTAGGGAAGAAGATCAGGGAGATAG-3Ј; b (forward, Ϫ1337 to Ϫ1318; reverse, Ϫ1181 to Ϫ1202), 5Ј-GCACTCCACTGCACAGAG TCA-3Ј and 5Ј-CCCACCTCAGCCTCCCAAAGT-3Ј; p16
INK4a
, 5Ј-AGAAAGA GGAGGGGCTGGCTGGTCA-3Ј and 5Ј-CAGCCGTCAGCCGAAGGCTCC A-3Ј. PCR was performed using HotStarTaq (QIAGEN) or a QuantiTect SYBR Green PCR kit (QIAGEN) on an i-Cycler (Bio-Rad).
Retroviral infection of murine myeloid progenitor cells. To determine the fetal genotype, once the liver was removed, the remainder of the embryonic tissue was used for preparing genomic DNA as previously described (5) . Primers were employed to distinguish disrupted and wild-type alleles using PCR (28) .
Recombinant retroviral plasmids were transfected into a GPϩE 86 packaging cell line as previously described (20) . Stable populations of packaging cells expressing the retrovirus were selected by serially separating green fluorescent protein-positive (GFP ϩ ) cells by fluorescence-activated cell sorter (FACS) until more than 95% of the cells were GFP ϩ . The transduction protocol has been previously described (19) . Briefly, embryonic day 13.5 fetal liver cells were prestimulated for 48 h in liquid cultures of IMDM (Invitrogen Corporation, Grand Island, NY) containing 20% fetal bovine serum (BioWhittaker, Walkersville, MD) supplemented with 100 ng/ml stem cell factor (SCF; PeproTech, Rocky Hill, NJ) and 200 U/ml IL-6 (PeproTech, Rocky Hill, NJ). Cells were subsequently transduced with viral supernatants on RetroNectin-treated non-tissue culture plates (TaKaRa Bio, Inc., Madison, WI) for 48 h in the presence of SCF and IL-6. Mast cell lines were then established from these transduced progenitors for immunoblot analysis (2) .
For methylcellulose colony assays, transduced fetal liver cells were incubated with1 g of phycoerythrin-conjugated c-Kit antibody/10 6 cells (PharMingen, San Diego, CA) for 20 min at 4°C. Cells were then washed twice with 0.5% bovine serum albumin in phosphate-buffered saline. GFP ϩ c-Kit ϩ cells were then separated by FACS. This enriched hematopoietic progenitor population of cells was plated at a concentration of 5,000 cells/ml in triplicate methylcellulose cultures (Stem Cell Tech, Inc., Vancouver, British Columbia, Canada) containing increasing concentrations of GM-CSF (0.01 to 2 ng/ml; PeproTech, Rocky Hill, NJ) or IL-3 (0.1 to 10 U/ml; PeproTech, Rocky Hill, NJ), and granulocyte macrophage CFU were scored on day 7 of culture.
Protein and RNA analysis. Viral supernatants were prepared using vesicular stomatitis virus G glycoprotein-pseudotyped retrovirus from the GP2-293 packaging cell line (Clontech). Infected HeLa cells were selected in puromycin before protein or RNA analysis. COS7-L cells were transfected using Lipofectamine 2000 (Invitrogen). Antibodies directed to human NF1 (10), human p14 ARF (Ab-1; Neomarkers), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (ab8245-100; Norus Biologicals), the MTG8 zinc finger domain (␣-ETO/MTG8 ZnF Ab-1; CalBiochem/EMD Biosciences), and RUNX1 (␣-N-RUNX1 and ␣-RHD-RUNX1; CalBiochem/EMD Biosciences) were used for immunoblot analysis. RNA was isolated using an RNeasy Mini kit (QIAGEN), and 10 g was run on a 1% formaldehyde gel and probed with a radiolabeled NF1 cDNA fragment encompassing exon 33, a 400-bp fragment of p14 ARF encompassing exon 1␤, or the full-length c-Myc and GAPDH cDNAs.
NF1 expression in primary AML samples. Total RNA was extracted from bone marrow samples of 49 AML patients obtained at the time of initial diagnosis. Written consent was obtained from all patients. The presence or absence of RUNX1-MTG8 was analyzed using standard reverse transcription (RT)-PCR procedures and/or cytogenetics. Each sample was analyzed for NF1 or porphobilinogen deaminase gene (PBGD) expression two times by real-time quantitative RT-PCR (QRT-PCR) with specific primers and fluorescence-labeled probes (TaqMan assay). To avoid amplification of homologous sequences and possible NF1 pseudogenes, we used primers from exons 37 and 38, which are separated by an intron of 3 kb to eliminate priming from genomic DNA (NF1 forward, 5Ј-GGACACTGCTCAATATCGCATTAC-3Ј; reverse, 5Ј-AGGTACAAGTTA AGGCAC ACAGAAGA-3Ј; probe, 5Ј-FAM-GACCGTAAACTCGGGTCAG AACTGCCTA-3Ј). To test whether the PCR would amplify DNA sequences, 0 to 50 ng of human genomic DNA was used as the template with no resulting product. When analyzed by gel electrophoresis, the QRT-PCR product obtained from patient samples was a single band of the expected size (96 bp). The RNA isolation, cDNA synthesis and input, cycling conditions, and PBGD expression measured for normalization were as described previously (39) . From each sample, the quantity of NF1 and PBGD mRNAs was measured in duplicate using serial dilutions of cell line RNA as a calibration curve. The PBGD mRNA primers used were as follows: forward, 5Ј-GGCAATGCGGCTGCAA-3Ј; reverse, 5Ј-GGGTACCCACGCGAATCAC-3Ј. They were used in combination with a VIC-labeled probe (5Ј-VIC-CATCTTTGGGCTGTTTTCTTCCGCC-3Ј). Total RNA was isolated using RNAzol (Campro Scientific). For cDNA synthesis, 1 g total RNA was reverse transcribed using random hexanucleotide primers. PCR was performed using universal mastermix (Applied Biosystems). Samples were heated for 2 min at 50°C and 10 min at 95°C and amplified for 45 cycles of 15 s at 95°C and 60 s at 60°C on an ABI/Prism 7700 sequence detector (Applied Biosystems).
Statistical analysis was performed using Minitab release 12 (Minitab, Inc.), and P values and confidence intervals determined using the nonparametric MannWhitney rank sum test. For example, in comparing AML to AML-M2 samples, for C1, n ϭ 34 and median ϭ 0.388 and for C2, n ϭ 15 and median ϭ 0.100; the point estimate for ETA1-ETA2 is 0.204, the 95.0% confidence interval for ETA1 Ϫ ETA2 is 0.073 to 0.365, W ϭ 974.5, and the test of ETA1 ϭ ETA2 versus ETA1 not ϭ ETA2 is significant (P ϭ 0.0071; adjusted for ties).
RESULTS

RUNX1, C/EBP␣, and ETS factors cooperate to regulate
NF1. Patients with NF1 mutations are at increased risk for the formation of JMML (59, 60) , but mutations in NF1 have not been reported in sporadic AML, leaving open the possibility that this tumor suppressor is regulated transcriptionally. Given the high frequency of disruption of RUNX1 in acute leukemia, we asked if RUNX1 regulates NF1. We identified 13 consensus RUNX1 binding sites in the human NF1 promoter, with 7 of these sites matching the narrower consensus sequence TGT/ cGGT (47) (Fig. 1A) . Because RUNX1 cooperates with C/EBP␣ and mutations in C/EBP␣ are associated with M2 AML (53), we also inspected the NF1 promoter for C/EBP␣ binding sites. Three of the C/EBP␣ binding sites were clustered near RUNX1 sites, similar to other genes that are coregulated by these factors (22, 31, 54, 57, 66) . This raised the possibility that NF1 is a transcriptional target of RUNX1 and C/EBP␣. We confirmed that RUNX1 and C/EBP␣ bind these sites in gel mobility shift assays (data not shown). In reporter assays, RUNX1 activated the NF1 promoter and the level of activation was enhanced by coexpression of the RUNX1 cofactor CBF␤, which increases RUNX1 DNA binding and stability (23, 24) (Fig. 1B and data not shown). In addition, C/EBP␣ activated NF1 approximately sevenfold, but this activation was lost when higher levels of C/EBP␣-expressing plasmid were used ( Fig. 1B and data not shown). When C/EBP␣ was coexpressed with RUNX1, these factors dramatically cooperated to activate the NF1 promoter over 80-fold (Fig. 1B) .
ETS family members also cooperate with RUNX1 to activate transcription, and ETS factor sites are also adjacent to the RUNX1 binding sites in the NF1 promoter (Fig. 1A) . Therefore, we tested whether the NF1 promoter can be regulated by RUNX1 and the ETS family members ETS2 and PU.1 in reporter assays. Similarly, ETS2 or PU.1 only modestly activated the NF1 promoter. However, when RUNX1 was coexpressed with ETS2, these factors cooperated to activate the NF1 promoter over 90-fold (Fig. 1B) . Thus, RUNX1 cooperates with C/EBP␣ and ETS2 to regulate NF1.
The presence of multiple RUNX1, ETS, and C/EBP␣ binding sites in the NF1 promoter prompted us to attempt to identify the RUNX1 binding sites that are required for regulation of NF1. Because of the large number of binding sites in this promoter, we did not attempt to mutate each site individually but performed deletion analysis of the promoter (Fig.  1A) . Deletion of the sequences from Ϫ2732 to Ϫ1285 reduced the ability of these factors to cooperatively activate NF1 (Fig.  1C, left side) . Further deletion to nucleotide Ϫ969 dramatically impaired the cooperative activation, and deletion to Ϫ548, which removes the last RUNX1 binding site, yielded only additive, not cooperative, transactivation (Fig. 1C, right  side) . Thus, the transcription factor binding sites clustered between the AvrII and Tth111I sites are most clearly required for the cooperative action of RUNX1, ETS2, and C/EBP␣, although other sites such as the cluster of sites approximately 2.3 kbp upstream of the transcriptional start may also contribute to the regulation of NF1.
To demonstrate specificity for the cooperative regulation of NF1, we used the Ϫ969 promoter fragment that contains a lone consensus RUNX1 binding site but retains some cooperative transactivation. We mutated the proximal RUNX1 consensus sequence CGTGGT at Ϫ758 to CGCGAG (Fig. 1D , left side) and tested the ability of RUNX1 and ETS2 to cooperatively activate this promoter. Compared to the minimal promoter (Ϫ59) that lacks all of the RUNX1 sites, RUNX1 and ETS2 once again cooperated to activate the Ϫ969 promoter (Fig. 1D , right side). Although RUNX1 still activated the mutant promoter, probably through a putative weak RUNX1 binding site at Ϫ661, only additive, not cooperative, effects were observed when RUNX1 was coexpressed with ETS2 with the mutant promoter (Fig. 1D, right side) .
The t(8;21) fusion protein represses NF1 gene expression. RUNX1-MTG8 (also known as AML1-ETO) represses genes that contain RUNX1 binding sites (43) . Therefore, we tested whether RUNX1-MTG8 could also regulate the NF1 promoter in reporter assays ( Fig. 2A and B) . RUNX1-MTG8 repressed NF1 transcription, whereas a point mutant (L148D) that fails to bind to DNA (37) or a C-terminal deletion mutant (⌬469) that truncates the fusion protein prior to the oligomerization domain, and therefore lacks association motifs for mSin3, N-CoR/SMRT, and HDACs (2, 37), failed to repress the NF1 promoter (Fig. 2B) . CBF␤ stimulates the DNA binding functions of the fusion protein, and as expected, the addition of this cofactor increased the ability of wild-type RUNX1-MTG8, but not the mutants, to repress NF1 (Fig. 2B) .
Based on our analysis of RUNX1-mediated transactivation, we used a subset of our deletion mutants of the NF1 promoter to determine the sequences required for RUNX1-MTG8-mediated repression. Deletion of the sequences from Ϫ3363 to Ϫ2732 had little effect on both the basal activity of the promoter and the ability of RUNX1-MTG8 to repress the promoter. Further deletion to Ϫ1285 reduced the basal activity of the promoter by 70%, but the ability of RUNX1-MTG8 to repress the promoter remained until deletion to Ϫ548 that removes all of the consensus RUNX1 binding sites (Fig. 2C) . This result prompted us to test the Ϫ969 promoter fragment with and without the RUNX1 consensus binding site (Fig. 1D ) to determine whether this site is sufficient to mediate RUNX1-MTG8-dependent repression. Although the level of repression by the fusion protein was somewhat lower in this assay, mutation of the RUNX1 binding site impaired RUNX1-MTG8-mediated repression (Fig. 2D) .
RUNX1-MTG8 binds the NF1 promoter in vivo. Given the results of the promoter analysis, we asked whether RUNX1-MTG8 associates with NF1 in the context of native chromatin. Kasumi-1 cells that contain t(8;21) were cross-linked with formaldehyde, and the DNA associated with RUNX1-MTG8 was isolated using ChIP. The RUNX1-MTG8-associated chromatin was then interrogated for the presence of NF1 promoter sequences using PCR. Primers flanking the clusters of RUNX1 binding sites labeled a and b in Fig. 3A were selected because the shearing of genomic DNA to 200 to 800 bp in size allows these primers to detect RUNX1-MTG8 bound to several of the perfect and consensus RUNX1 binding sites. Using antibodies directed to RUNX1, we were able to detect both the a and b clusters of RUNX1 binding sites in NF1 associated with RUNX1-MTG8 in Kasumi-1 cells (Fig. 3B, anti-N-RUNX1 , upper and middle parts). As a control, the NF1 promoter failed to copurify with antibodies directed to RUNX2 and RUNX3, which are not expressed at detectable levels in Kasumi-1 cells (data not shown), or antibodies directed to the yeast transcription factor GAL4 (Fig. 3B, upper part) . Moreover, an antibody directed to the DNA binding domain of RUNX1 (␣-RHD) that does not recognize RUNX1 when bound to DNA also was used as a negative control (Fig. 3B) . Because Kasumi-1 cells also express RUNX1, we used anti-MTG8 in ChIP analysis to separate the fusion protein from wild-type RUNX1. NF1 copurified with anti-MTG8 from Kasumi-1 cells, indicating that the fusion protein was associated with NF1 in these cells (Fig. 3B) . By contrast, the NF1 promoter was not detected using anti-MTG8 in HEL cells (Fig.  3C) , which lack the fusion protein. QRT-PCR demonstrated at least an eightfold (three-cycle) enhancement of NF1 promoter sequences associated with anti-RUNX1 compared to control antibodies and essentially no association with the p16 ink4A promoter, which lacks RUNX1 binding sites (Fig. 3D) .
To confirm that RUNX1 can also contact the NF1 promoter in the absence of the background of the fusion protein, we performed ChIP assays using HEL cells that express easily detectable levels of RUNX1 but fail to express RUNX2 or RUNX3. Only antibodies directed to RUNX1 copurified with the NF1 promoter sequences (Fig. 3C) . Thus, NF1 is bound by both RUNX1 and RUNX1-MTG8.
RUNX1-MTG8 represses endogenous NF1 gene expression. RUNX1-MTG8 can repress the NF1 promoter in reporter assays (Fig. 2) and associates with the NF1 promoter on native chromatin (Fig. 3) . Therefore, we asked whether the fusion protein represses endogenous NF1. Because we did not expect complete silencing of NF1, a potential obstacle to measuring repression of an endogenous gene is the stability of its mRNA or protein. Therefore, we first determined the stability of NF1 protein (neurofibromin) and mRNA. HeLa or Cos7-L cells were cultured in the presence of cycloheximide or actinomycin D, and samples removed at various times after addition of the drug for preparation of protein samples or RNA, respectively. Immune and RNA blot analyses were used to determine the half-lives (t 1/2 s) of NF1 protein and mRNA ( Fig. 4A and B) . Compared to c-Myc, which has a short t 1/2 , the NF1 protein and mRNA were long-lived, with a t 1/2 of NF1 protein of over 10 h and a t 1/2 of NF1 mRNA of nearly 8 h.
The stability of the NF1 mRNA and protein required that we maintain expression of RUNX1-MTG8 for several days. Although counterintuitive, it is well established that the fusion protein inhibits cell cycle progression and its expression is (2, 8). Therefore, we used retroviral infection of HeLa cells, a cell type that allows RUNX1-MTG8 expression for several days with minimal effects on the cell cycle (39) , to express RUNX1-MTG8. Three days after infection, RUNX1-MTG8-expressing cells had reduced levels of NF1 mRNA (Fig. 4C) . The level of NF1 protein was reduced at 5 and 8 days after RUNX1-MTG8 expression, subsequent to the reduction of NF1 mRNA ( Fig.  4C and 4D ). As a negative control, the levels of GAPDH were unaffected, whereas the levels of a known direct target of RUNX1-MTG8, p14 ARF (39) , were also repressed ( Fig. 4C and  D) . To confirm the RUNX1-MTG8-mediated repression of NF1 in a second cell type, we transfected COS7-L cells, which were selected based on their high transfection efficiency. Using a RUNX1-MTG8-IRES-GFP-expressing plasmid, we confirmed that greater than 95% of the cells expressed GFP as measured by FACS analysis 3 to 5 days after transfection (data not shown). Once again, RUNX1-MTG8, but not a mutant that fails to bind to DNA (L148D) or a mutant that lacks key corepressor recruitment domains (⌬469), repressed NF1 ( Fig.  4E and F) . Although the inactive mutants of RUNX1-MTG8 were expressed at high levels, the wild-type protein was expressed at levels comparable to those found in Kasumi-1 cells (Fig. 4F) . Thus, NF1 can be repressed by RUNX1-MTG8.
RUNX1-MTG8 expression phenocopies loss of Nf1 for growth of myeloid cells induced by GM-CSF.
Although the NF1 promoter is not highly conserved between humans and mice, the murine promoter contains four perfect RUNX1 binding sites, two of which are clustered similar to the a and b sites shown in Fig. 3 . Therefore, we tested the effects of RUNX1-MTG8 on the expression of Nf1 in primary myeloid progenitor cells. For comparison, we isolated myeloid progenitor cells from embryonic day 13.5 livers of mice derived from breeding Nf1 ϩ/Ϫ mice, which yielded wild-type, Nf1 ϩ/Ϫ , and Nf1 Ϫ/Ϫ embryos (fetal liver cells were used due to the midgestation lethality observed in Nf1 Ϫ/Ϫ embryos) (7, 28) . Fetal liver hematopoietic progenitor cells of each genotype were infected with RUNX1-MTG8-expressing retroviruses, and repression of Nf1 in the GPF-expressing population was observed using immunoblot analysis after FACS-based cell sorting (Fig. 5A) .
One of the effects of loss of NF1 is to stimulate RASdependent signaling due to the loss of negative regulation (5, 12) . However, these effects are small and difficult to measure accurately. Nevertheless, these small changes in RAS-GTP levels have dramatic effects on signaling (25, 27, 36) . A more robust assay for the loss of NF1 function is the observation that loss of NF1 sensitizes myeloid progenitor cells to the growthpromoting effects of GM-CSF, but not IL-3 (5, 15, 35) . When equal numbers of infected progenitor cells were cultured in methylcellulose containing IL-3, a similar number of colonies were observed in all genotypes in the presence or absence of on January 6, 2014 by Washington University in St. Louis http://mcb.asm.org/ the fusion protein, indicating that RUNX1-MTG8 had little or no effect on the growth of myeloid progenitor cells cultured in IL-3 (Fig. 5B) . However, when cultured in methylcellulose containing GM-CSF, RUNX1-MTG8 expression dramatically increased the number of colonies formed in all but the highest levels of GM-CSF (Fig. 5C ). In fact, the RUNX1-MTG8-expressing cells in a wild-type or heterozygous Nf1 background grew similarly to Nf1-null cells (Fig. 5C ). However, RUNX1-MTG8 did not further enhance the number of colonies formed when both alleles of NF1 were deleted (Fig. 5C , RUNX1-MTG8/NF1 Ϫ/Ϫ ), suggesting that the RUNX1-MTG8-mediated enhancement of growth was due to the repression of NF1 and was not due to a general enhancement of proliferation.
NF1 mRNA is underrepresented in M2 AML. Patients with NF1 mutations are at increased risk for the formation of JMML, but mutations in NF1 have not been reported in sporadic AML. Therefore, we defined the levels of expression of NF1 in AML patient samples to determine whether NF1 is regulated epigenetically. We used QRT-PCR to measure NF1 mRNA levels in AML (Fig. 6A) . NF1 was differentially expressed over a range of nearly 3 logs. Given that hematopoietic cells containing only one allele of Nf1 display sensitivity to cytokines, this finding suggests that NF1 levels may be affected in many forms of AML. Nevertheless, we noted that the median levels of NF1 mRNA in FAB M2 AML [with and without t(8;21)] were lower than the median of the other AML samples ( Fig. 6A ; 95% confidence interval, 0.073 to 0.365; P value of 0.0071). Because t(8;21) is frequently present in M2 AML, we further subdivided M2 leukemia to compare AML samples with and without t(8;21). Compared to the other subtypes of AML, NF1 mRNA levels were about 50% lower in the AML M2 samples without t(8;21) ( Fig. 6A ; 95% confidence interval, Although the levels of NF1 mRNA appeared to be lower in patient samples containing t(8;21) (Fig. 6A) , the variability of NF1 expression across various subtypes of AML complicates the interpretation. Therefore, we sought to confirm that RUNX1-MTG8 was associated with the NF1 promoter in t(8; 21)-containing leukemic blasts. We obtained a fresh bone marrow aspirate from a patient who had relapsed t(8;21)-containing AML with a relatively high blast count (66%). Proteins were cross-linked to DNA using formaldehyde and subjected to ChIP analysis using anti-N-terminal RUNX1 coupled with QRT-PCR (Fig. 6B, upper part) . In addition, we were able to obtain several vials of marrow from this same patient which had only been frozen for a few days and that retained very high viability (Ͼ90%) to perform a second round of ChIP using anti-ZnF-MTG8 (anti-ETO Ab-1, Fig. 6B, middle part) . Both anti-N-RUNX1 and anti-ZnF-MTG8 yielded a positive signal compared to an irrelevant control antibody or to the p16 ink4a promoter (Fig. 6B , bottom part and data not shown), which places RUNX1-MTG8 at the endogenous NF1 promoter in leukemic blasts.
DISCUSSION
Mutations in NF1 represent a common familial cancer syndrome, but de novo mutations of NF1 in leukemia are rare (29, 42, 55, 56) . We have established that NF1 is a direct transcriptional target of RUNX1 and the t(8;21) fusion protein. Given that t(8;21) is the most frequent chromosomal translocation in AML (58), our results suggest that regulation of NF1 is a frequent event in AML. In addition, RUNX1 is inactivated by point mutations in M0 AML, and RUNX1-dependent gene regulation is disrupted directly or indirectly by other chromosomal translocations in myeloid and B-cell acute leukemia (43) . Therefore, up to 20% of acute leukemias may show misregulation of NF1 expression through disruption of RUNX1 function alone. In addition, C/EBP␣ cooperated with RUNX1 to activate NF1 (Fig. 1) , implying that this factor may also regulate NF1. Although we did not focus on C/EBP␣, mutations in CEBP〈 are associated with the M2 subgroup of AML (49, 53) . Thus, NF1 may also be misregulated in these cases. Because phenotypes such as sensitivity to GM-CSF are associated with haploinsufficiency of NF1 (35) , even a modest reduction in the levels of NF1 should stimulate proliferation and survival (3, 26) and cooperate with secondary mutations. In this regard, it is notable that c-KIT, but not other tyrosine kinase receptors, is mutated at high frequency in t(8;21)-containing AML, and NF1 modulates signals emanating from c-KIT (4, 26, 33, 62) .
In addition to NF1, the p14 ARF tumor suppressor is also repressed by RUNX1-MTG8 (Fig. 4) (39) . p14 ARF is induced by oncogenic activation such as overexpression of c-Myc or mutational activation of RAS (14) . Once induced, p14 ARF binds to and inactivates MDM2, which stabilizes the p53 tumor suppressor, to trigger growth arrest or apoptosis. In addition, p14
ARF has p53-independent activity in growth inhibition (63) . Loss of p19 ARF expression and loss of NF1 expression cooperate to induce multiple tumor types (32) . The repression of NF1 and p14 ARF suggests a model for how RUNX1-MTG8 may set the stage for the development of leukemia. The repression of NF1 may stimulate RAS activity or sensitize the cells to pro- (32) . Moreover, when only one allele of each tumor suppressor was deleted, a situation that may be more analogous to repression, the latency of tumor formation was shortened (32) . Thus, repression of NF1 and p14 ARF would be anticipated to cooperate with other mutations, including epigenetic regulation of p16 ink4A or oncogenic activation of tyrosine kinases such as c-KIT, in leukemogenesis.
The analysis of the expression of a given gene in AML samples is extremely difficult because only the endpoint (transformed cells) can be used without the appropriate normal control cell that would match the leukemic blast. This is further complicated by differences in the genetic backgrounds of the individuals, which can greatly affect the basal transcription of genes (9, 48, 51) . When these differences are coupled with secondary mutations, and the varied AML subtypes with distinct phenotypes and blocks of differentiation, it is extremely difficult to interpret subtle differences in gene expression. Our cohort of 49 AML samples contained an unusually high number of AML M2 (Fig. 6) , which aided our analysis of this subgroup. Even so, the differences in NF1 mRNA levels were not as distinct as those observed previously for p14 ARF or CEBPA (39, 52) . Given the multitude of data indicating that NF1 is a direct transcriptional target of RUNX1-MTG8 (Fig. 3  to 6 ), including detecting the fusion protein bound to the NF1 promoter in leukemic blasts, this may simply indicate that NF1 is a more widespread target for gene silencing in AML, thereby making repression by RUNX1-MTG8 less evident. Nevertheless, in our cohort the results were significant at the 95% confidence level.
The observation that RUNX1-MTG8 represses NF1 and stimulates the growth of isogenic myeloid progenitor cells isolated from inbred mouse strains in response to GM-CSF (Fig.  5 ) may also have therapeutic implications. Our results suggest that t(8;21)-containing leukemic blasts may be hyperproliferative in response to GM-CSF or SCF and therefore sensitive to FIG. 6 . Levels of NF1 mRNA in AML samples. NF1 mRNA levels in 49 AML patient samples were determined using QRT-PCR and normalized using the porphobilinogen deaminase gene (PBGD) as an internal control for the amount of mRNA added to each reaction mixture. The level of NF1 mRNA in each sample was plotted on a logarithmic scale. The median is indicated with a solid bar with the value shown beside it. The samples were subdivided into non-M2 AML, FAB M2 without t(8;21), and t(8;21)-containing samples. (B) ChIP analysis of the NF1 promoter from a t(8;21)-containing patient sample. The antibodies used are described in more detail in the legend to Fig. 3 . The a primers (Fig. 3A) were used for the analysis shown. The lower part shows amplification of the p16 ink4a promoter as a control. RFU, relative fluorescence units. 
